Nippon Shinyaku Exercises $30 Million U.S. Commercialization Option for AB2 Bio's Tadekinig Alfa in Ultra-Rare Pediatric Hyperinflammatory Syndrome
核心洞察
Nippon Shinyaku has exercised its exclusive U.S. commercialization option for Tadekinig alfa, triggering a $30 million payment to AB2 Bio following positive FDA interactions.
Tadekinig alfa targets Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome (搜索) caused by NLRC4 (搜索) and XIAP (搜索) mutations, an ultra-rare pediatric disease with no approved therapies.
AB2 Bio is eligible to receive up to $600 million in total milestones and royalties, while retaining worldwide rights for all other indications and ex-U.S. rights for the lead indication.
Nippon Shinyaku Co., Ltd. has exercised its exclusive U.S. commercialization option for Tadekinig alfa, AB2 Bio Ltd. (搜索)'s lead investigational therapy, the companies announced on July 30, 2026. The decision follows what AB2 Bio described as positive interactions with the U.S. Food and Drug Administration and triggers a $30 million option exercise payment to the Lausanne-based biotechnology company.
The agreement covers Tadekinig alfa for the treatment of Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome (搜索) in patients with NLRC4 (搜索) and XIAP (搜索) mutations — an ultra-rare, potentially life-threatening pediatric condition for which no FDA-approved therapies currently exist.
"This progress represents an important milestone for AB2 Bio and, more importantly, for patients and families affected by this devastating disease," said Dr. Djordje Filipovic, Chief Executive Officer of AB2 Bio. "Nippon Shinyaku's decision reflects the strength of our clinical program and our shared confidence in Tadekinig alfa. Together, we are well positioned to accelerate the delivery of this potential therapy to patients in the United States."
Financial Terms and Deal Structure
Under the terms of the agreement, AB2 Bio is eligible to receive up to $100 million in development milestone payments and up to $500 million in commercial milestone and royalty payments, bringing the total potential value to $600 million. The company had previously received a $6 million option fee when the option and license agreement was signed in January 2025.
Nippon Shinyaku now holds exclusive commercialization rights in the United States for the licensed indication. AB2 Bio retains exclusive rights to all other indications in the United States and to all indications outside the United States. The company will continue to lead Biologics License Application (BLA) preparation and other U.S. regulatory activities. Closing of the transaction may require clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Disease Background and Unmet Need
Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome (搜索) is caused by mutations in the NLRC4 (搜索) and XIAP (搜索) genes. Patients develop sharply elevated levels of free interleukin-18 (IL-18 (搜索)), a signaling protein that drives systemic inflammation. The condition can progress rapidly to multiorgan dysfunction, irreversible organ damage, and in the most severe cases, death. The disease primarily affects infants and young children, and standard care manages symptoms rather than the underlying mechanism.
The Phase 3 clinical program enrolled patients with genetically confirmed NLRC4 (搜索) or XIAP (搜索) mutations who continued to experience severe, life-threatening hyperinflammation despite standard supportive care.
Mechanism of Action and Regulatory Designations
Tadekinig alfa is a recombinant human interleukin-18 binding protein (IL-18BP) designed to neutralize excess free IL-18 (搜索), a key driver of hyperinflammation. By restoring the natural balance between IL-18 and its endogenous inhibitor, the therapy is designed to reduce excessive inflammation and represents a novel therapeutic approach targeting the underlying disease mechanism rather than its symptoms.
AB2 Bio has successfully completed its Phase 3 clinical program in the lead indication and has demonstrated clinical proof of concept in three additional life-threatening orphan diseases. Tadekinig alfa has received Orphan Drug Designation in both the United States and Europe, as well as Breakthrough Therapy and Rare Pediatric Disease Designations from the FDA, making it potentially eligible for a Priority Review Voucher upon approval.
"AB2 Bio has established a leading position in the development of therapies targeting IL-18 (搜索)-driven diseases," said Dr. Toru Nakai, President and Representative Director of Nippon Shinyaku. "There are currently no FDA-approved therapies for this rare and potentially life-threatening disease. We are pleased to expand our partnership with AB2 Bio and look forward to bringing Tadekinig alfa to patients in the United States."
Dr. Andrea Pfeifer, Chair of AB2 Bio, added: "By combining our leadership in IL-18 (搜索) biology with Nippon Shinyaku's proven rare disease expertise, we are accelerating the path to patients while preserving significant long-term value through our retained global rights and the continued development of Tadekinig alfa across additional IL-18-driven indications."